Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of NouvNeu001 injection in moderate to advanced Parkinson's disease
CTR20233825Phase 2Active
- Sponsor
- AIM Bio
- Start
- Jan 2024
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of NOUVNEU001 in Parkinson's disease (PD), sponsored by AIM Bio. Started Jan 2024; status: active.
02
Drugs
NOUVNEU001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20233825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233825.